• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 usnic 酸的噻唑并噻吩作为 SARS-CoV-2 病毒主要蛋白酶抑制剂的潜力。

The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses.

机构信息

Department of Medicinal Chemistry, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, 630090 Novosibirsk, Russia.

Synchrotron Radiation Facility SKIF, G.K. Boreskov Institute of Catalysis SB RAS, 630559 Koltsovo, Russia.

出版信息

Viruses. 2024 Jan 31;16(2):215. doi: 10.3390/v16020215.

DOI:10.3390/v16020215
PMID:38399993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10893357/
Abstract

Although the COVID-19 pandemic caused by SARS-CoV-2 viruses is officially over, the search for new effective agents with activity against a wide range of coronaviruses is still an important task for medical chemists and virologists. We synthesized a series of thiazolo-thiophenes based on (+)- and (-)-usnic acid and studied their ability to inhibit the main protease of SARS-CoV-2. Substances containing unsubstituted thiophene groups or methyl- or bromo-substituted thiophene moieties showed moderate activity. Derivatives containing nitro substituents in the thiophene heterocycle-just as pure (+)- and (-)-usnic acids-showed no anti-3CL activity. Kinetic parameters of the most active compound, , were investigated, and molecular modeling of the possible interaction of the new thiazolo-thiophenes with the active site of the main protease was carried out. We evaluated the binding energies of the ligand and protein in a ligand-protein complex. Active compound was found to bind with minimum free energy; the binding of inactive compound is characterized by higher values of minimum free energy; the positioning of pure (+)-usnic acid proved to be unstable and is accompanied by the formation of intermolecular contacts with many amino acids of the catalytic binding site. Thus, the molecular dynamics results were consistent with the experimental data. In an in vitro antiviral assay against six strains (Wuhan, Delta, and four Omicron sublineages) of SARS-CoV-2, demonstrated pronounced antiviral activity against all the strains.

摘要

虽然由 SARS-CoV-2 病毒引起的 COVID-19 大流行已正式结束,但寻找对广泛冠状病毒具有活性的新有效药物仍然是医学化学家​​和病毒学家的重要任务。我们基于 (+)-和 (-)-usnic 酸合成了一系列噻唑并噻吩,并研究了它们抑制 SARS-CoV-2 主要蛋白酶的能力。含有未取代噻吩基团或甲基或溴代噻吩部分的物质表现出中等活性。含有噻吩杂环中硝基取代基的衍生物——就像纯 (+)-和 (-)-usnic 酸一样——没有抗 3CL 活性。研究了最活性化合物的动力学参数,并对新噻唑并噻吩与主蛋白酶活性位点可能的相互作用进行了分子建模。我们评估了配体和蛋白质在配体-蛋白质复合物中的结合能。活性化合物 被发现与最小自由能结合;非活性化合物 的结合以最小自由能的更高值为特征;纯 (+)-usnic 酸的定位被证明不稳定,并伴有与催化结合位点的许多氨基酸形成分子间接触。因此,分子动力学结果与实验数据一致。在针对 SARS-CoV-2 的六种株系(武汉、Delta 和四种奥密克戎亚谱系)的体外抗病毒测定中, 对所有株系均表现出明显的抗病毒活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/cad307e119ab/viruses-16-00215-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/3144835df917/viruses-16-00215-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/3e0f31fc305d/viruses-16-00215-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/e35f90515fc7/viruses-16-00215-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/a0c99013e8bc/viruses-16-00215-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/12b849b54a5c/viruses-16-00215-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/6e7909764a33/viruses-16-00215-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/cad307e119ab/viruses-16-00215-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/3144835df917/viruses-16-00215-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/3e0f31fc305d/viruses-16-00215-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/e35f90515fc7/viruses-16-00215-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/a0c99013e8bc/viruses-16-00215-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/12b849b54a5c/viruses-16-00215-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/6e7909764a33/viruses-16-00215-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8919/10893357/cad307e119ab/viruses-16-00215-g007.jpg

相似文献

1
The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses.基于 usnic 酸的噻唑并噻吩作为 SARS-CoV-2 病毒主要蛋白酶抑制剂的潜力。
Viruses. 2024 Jan 31;16(2):215. doi: 10.3390/v16020215.
2
(+)-Usnic Acid and Its Derivatives as Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses.(+)-麦角酸及其衍生物作为广泛谱 SARS-CoV-2 病毒抑制剂。
Viruses. 2022 Sep 29;14(10):2154. doi: 10.3390/v14102154.
3
Chetomin, a SARS-CoV-2 3C-like Protease (3CL) Inhibitor: Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis.切托明,一种 SARS-CoV-2 3C 样蛋白酶(3CL)抑制剂:筛选、酶对接、分子动力学和药代动力学分析。
Viruses. 2023 Jan 15;15(1):250. doi: 10.3390/v15010250.
4
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
5
In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.通过分子对接、MMGBSA 预测结合能计算和分子动力学模拟,从计算机上鉴定潜在的关键 SARS-CoV-2 3CL 水解酶(Mpro)抑制剂。
PLoS One. 2020 Jul 24;15(7):e0235030. doi: 10.1371/journal.pone.0235030. eCollection 2020.
6
Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.基于芹菜素的双黄酮衍生物作为潜在治疗 SARS-CoV-2 病毒蛋白酶(3CLpro)的药物的评价:通过分子对接、分子动力学和量子力学研究。
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):5915-5945. doi: 10.1080/07391102.2022.2098821. Epub 2022 Jul 18.
7
Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.虚拟双体系单盒:绝对结合自由能计算的非平衡化学技术:应用于 SARS-CoV-2 主蛋白酶配体。
J Chem Theory Comput. 2020 Nov 10;16(11):7160-7172. doi: 10.1021/acs.jctc.0c00634. Epub 2020 Oct 22.
8
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.羟乙胺类似物的抗病毒评估:针对 SARS-CoV-2 主蛋白酶(3CLpro)的抑制剂,一种虚拟筛选和模拟方法。
Bioorg Med Chem. 2021 Oct 1;47:116393. doi: 10.1016/j.bmc.2021.116393. Epub 2021 Sep 4.
9
Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.抗 SARS-CoV-2 活性氯喹及其类似物的理论研究及主要蛋白酶抑制剂的计算机筛选
J Proteome Res. 2020 Nov 6;19(11):4706-4717. doi: 10.1021/acs.jproteome.0c00683. Epub 2020 Oct 7.
10
Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches.通过虚拟筛选方法鉴定松萝酸的吡唑衍生物作为新型严重急性呼吸综合征冠状病毒2主蛋白酶抑制剂
Mol Biotechnol. 2024 Apr;66(4):696-706. doi: 10.1007/s12033-023-00667-5. Epub 2023 Feb 8.

引用本文的文献

1
Exploring Thiophene Derivatives: Synthesis Strategies and Biological Significance.探索噻吩衍生物:合成策略与生物学意义。
Med Chem. 2025;21(1):11-31. doi: 10.2174/0115734064326879240801043412.

本文引用的文献

1
Structure-based design of SARS-CoV-2 papain-like protease inhibitors.基于结构的 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂设计。
Eur J Med Chem. 2024 Jan 15;264:116011. doi: 10.1016/j.ejmech.2023.116011. Epub 2023 Dec 5.
2
The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒的主要蛋白酶3CLpro:如何化敌为友。
Front Bioeng Biotechnol. 2023 Jun 29;11:1187761. doi: 10.3389/fbioe.2023.1187761. eCollection 2023.
3
FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment.
美国食品药品监督管理局(FDA)完全批准新冠病毒抗病毒治疗药物帕罗韦德(Paxlovid)。
JAMA. 2023 Jun 27;329(24):2118. doi: 10.1001/jama.2023.9925.
4
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.2020 年至 2022 年 SARS-CoV-2 主蛋白酶抑制剂的研究进展。
Eur J Med Chem. 2023 Sep 5;257:115491. doi: 10.1016/j.ejmech.2023.115491. Epub 2023 May 22.
5
Covid-19: WHO declares end of global health emergency.新冠疫情:世界卫生组织宣布全球卫生紧急状态结束。
BMJ. 2023 May 9;381:1041. doi: 10.1136/bmj.p1041.
6
Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants.人类气道和鼻腔类器官揭示了 SARS-CoV-2 新兴变异株不断增强的复制适应性。
Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2300376120. doi: 10.1073/pnas.2300376120. Epub 2023 Apr 17.
7
SARS-CoV-2 polyprotein substrate regulates the stepwise M cleavage reaction.SARS-CoV-2 多蛋白底物调节逐步 M 裂解反应。
J Biol Chem. 2023 May;299(5):104697. doi: 10.1016/j.jbc.2023.104697. Epub 2023 Apr 10.
8
The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.具有免疫逃逸特性的新冠病毒奥密克戎亚变体迅速崛起:XBB.1.5和BQ.1.1亚变体。
MedComm (2020). 2023 Mar 15;4(2):e239. doi: 10.1002/mco2.239. eCollection 2023 Apr.
9
Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.SARS-CoV-2 变异株刺突突变与疫苗研发的研究进展。
Med Res Rev. 2023 Jul;43(4):932-971. doi: 10.1002/med.21941. Epub 2023 Mar 16.
10
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.在体外用和体内比较 3CL 蛋白酶抑制剂恩赛特韦和奈玛特韦对 SARS-CoV-2 的疗效。
J Antimicrob Chemother. 2023 Apr 3;78(4):946-952. doi: 10.1093/jac/dkad027.